Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This exploratory pilot study found that topical sildenafil and minoxidil both significantly increased hair counts in male patients with androgenic alopecia, with varying effects at different scalp regions.

This review discusses various anti-androgen treatments for hirsutism, including androgen receptor blockers and inhibitors, and emphasizes the role of diagnosis in selecting the most appropriate therapy, but reports no new clinical results.

In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.

This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

Ethosomes improve finasteride delivery through skin for hair loss treatment.

This study reports that incomplete information in a reverse supply chain can lead to efficiency losses, but a two-part tariff contract for the remanufacturer may improve performance by eliciting private information from collectors.

This guideline discusses the evaluation and treatment of hirsutism in premenopausal women, recommending oral contraceptive pills or antiandrogens as initial therapies with weak support from low-quality evidence.

This study investigated hair enhancement treatments used by transgender men in the U.S. and found that while 90% used testosterone therapy, 44.1% sought additional facial hair enhancement options such as topical minoxidil, despite significant safety concerns reported by 77.3% of participants.

This review addresses concerns about finasteride and high-grade prostate cancers but reports no new clinical results.

This case report highlights the growing trend of adolescents using Finasteride off-label for early hair loss, driven by online misinformation and psychological distress, despite potential side effects and hormonal concerns.

This review discusses existing and emerging treatments for hirsutism, highlighting new home-use laser devices, and reports no new clinical results; the authors note that permanent hair removal remains elusive.

This review explores the evaluation and treatment of hirsutism, emphasizing a systematic approach to uncovering its causes and recommending combination therapies for effective management, but presents no new results.

This study reports that ethosomal formulations, such as ethosomal acyclovir and minoxidil, improved therapeutic effectiveness by enhancing skin permeation, leading to faster healing of herpes labialis lesions and increased skin absorption compared to standard formulations.

This commentary highlights that transgender patients are often dissatisfied with standard hormone replacement therapy for hair-related goals, emphasizing the need for dermatologists to provide informed guidance and tailor treatments.

This article reviews idiopathic hirsutism, focusing on its definition, diagnosis, causes, and treatment options, without presenting new clinical findings.

This article discusses the combination of mechanical hair removal and medication use for hirsutism improvement, noting that no drugs are approved for this condition in North America, and calls for well-designed comparative studies.

This literature review suggests that herbal extracts show promise as antiandrogenic agents for androgen-related conditions, potentially offering a natural alternative with fewer side effects than synthetic medications.

This article discusses solitary hirsutism, emphasizing that treatment is mostly cosmetic unless contraception is also desired, and reports no new clinical results.

This study evaluated high-dose oral minoxidil treatment in 57 patients with androgenetic alopecia and found it improved hair density by 10-30% in most cases, but 24.6% experienced adverse effects like hypertrichosis and tachycardia, indicating further research is needed to optimize safety and efficacy.

This source highlights topical minoxidil as the first-line treatment for androgenetic alopecia in both genders and finasteride for men, while also identifying dutasteride, low-dose oral minoxidil, and topical finasteride as promising future options.